<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/787B6E58-7171-4E19-86B1-38D99F6ECE76"><gtr:id>787B6E58-7171-4E19-86B1-38D99F6ECE76</gtr:id><gtr:firstName>James MacDonald</gtr:firstName><gtr:surname>Brewer</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3E91007A-C382-4933-9141-61911A5056ED"><gtr:id>3E91007A-C382-4933-9141-61911A5056ED</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Garside</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FE00069X%2F2"><gtr:id>76342031-F399-444D-9050-E51BF781B97B</gtr:id><gtr:title>Investigating the contributions of inflammation and antigen depot to adjuvant function in vivo.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/E00069X/2</gtr:grantReference><gtr:abstractText>While we think that we understand how vaccines work, it is clear that we don't really know how the magnitude and type of immune response a vaccine induces is controlled. This is important, as a number of vaccines are only feasible if we can modulate the size and type of immune response generated. In vaccination, this function is performed by 'adjuvants' and we don't really understand how they work either. Experiments in culture suggest an important role for cells, known as dendritic cells, in controlling vaccine-induced responses. However, cells of the immune system do not work in isolation and it has been difficult to analyse the interactions of dendritic cells and other immune cells in real physiological environments. We have therefore developed a number of state of the art techniques that allow us to characterise the function of dendritic cells, their interactions with other immune cells and the effects of these processes on vaccine-induced responses, in a physiological environment in real time. Only by analysing these interactions in a physiological environment in real time, can we understand how vaccines and adjuvants control the magnitude and type of immune response. This fundamental information will help produce agents to enhance the immune response to vaccines against infections or cancers, as well as to turn off inappropriate immune responses associated with diseases such as allergy, asthma and autoimmunity.</gtr:abstractText><gtr:technicalSummary>The reasons why certain vaccine adjuvants and/or delivery systems are more or less effective at inducing immune responses or promoting the preferential induction of particular types of response are unknown. Specifically, it is unclear what impact inflammatory and depot-forming adjuvants have on APC factors known to regulate these responses, in particular phenotype, activation state, magnitude and duration of antigen presentation and the consequences these factors have on T cell activation, differentiation and function. Furthermore, very few of these parameters have been defined for these agents in vivo. This is a significant omission as it is clear that the component parts of the immune system do not work in isolation and their interactions are dynamic and occur in distinct and specialised micro- and macroanatomical locations that can only be fully determined in real time, in the physiological context, in vivo. Therefore, in this application we will analyse the impact that inflammatory and depot-forming adjuvants have on the phenotype, activation state, processing and presenting capacity of APC and the subsequent consequences of this for T cell activation, differentiation and function. Only by performing such detailed and fundamental studies in vivo can we fully understand the cellular and molecular interactions that control the immune response. This information is a prerequisite if we are truly to design, build and target vaccines and therapeutic strategies effectively</gtr:technicalSummary><gtr:fund><gtr:end>2010-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2009-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>101213</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCB Pharma</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCB Celltech</gtr:department><gtr:description>Collaboration with UCB on cell migration in inflammation</gtr:description><gtr:id>0328904B-CC4A-4D2E-B49D-E40E66D077D7</gtr:id><gtr:impact>We are in discussion with UCB to establish joint PhD projects and possibly a programme.</gtr:impact><gtr:outcomeId>56dd827b309f36.66847257-1</gtr:outcomeId><gtr:partnerContribution>UCB funded the research with a PhD project.
The hosted the PhD student to perform detailed cell phenotyping (CyTOF)</gtr:partnerContribution><gtr:piContribution>UCB were interested in applying the technologies we have developed in investigating the traffic of cells from sites of inflammation to the draining lymph node. Specifically the ability to identify antigen presenting cells in vivo and the ability to photoswitch inflamed tissues to perform unbiased cell tracking</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>&quot;Adjuvants: Where they go, what they do and how they do it&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BC41041C-1F15-4E26-B7D1-ECFF8A837285</gtr:id><gtr:impact>This was part of an industry facing conference series of Immunopotentiators in Modern Vaccines. This type of interaction previously yeilded the collaboration with CSL on mechanism of action studies. My main aim here is to raise the profile of MOA studies, this has become easier since vaccine licensing agencies are demanding more of this information.

Discussion with Novartis regarding their vaccine adjuvant program.</gtr:impact><gtr:outcomeId>545cb77a009c99.16155741</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Society for Immunology Annual Congress - Plenary Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>19074493-DC7B-4E4B-BB33-46237BC93AC6</gtr:id><gtr:impact>The talk - Imaging Adjuvant Induced Responses In Vivo; provoked much interest in the work from this project. There is a great deal of confusion surrounding how Alum adjuvants work. Platforms such as this plenary session allow us to raise the profile of the area and directly tackle areas of confusion.

A number of contacts were made, and further presentations are planned in UK and abroad.</gtr:impact><gtr:outcomeId>545cb65e62edb5.00691868</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>There are over 6 billion vaccine doses administered each year, most containing aluminium-based adjuvants (Alum), yet we still do not have a complete understanding of their mechanisms of action. From the discovery of Alum in 1926, the formation of a local reaction at the injection site, called a depot, has been proposed as part of the mechanism of action. We disproved this hypothesis, demonstrating that events occuring very rapidly (&amp;lt;2h) drive the adjuvant effect.</gtr:description><gtr:exploitationPathways>The studies indicate the narrow time-window of Alum adjuvant activity, allowing the field to progress in identifying the mechanism of action of this and other adjuvants.</gtr:exploitationPathways><gtr:id>9E4DC987-3475-4BAE-A87B-FB26691EE82F</gtr:id><gtr:outcomeId>56dd80850f98e2.73830424</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C0771A19-530B-4C15-ACA2-D58AA74FBD50</gtr:id><gtr:title>Antigen presentation kinetics control T cell/dendritic cell interactions and follicular helper T cell generation in vivo.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33c6706b04188961c90bb697b60e0b22"><gtr:id>33c6706b04188961c90bb697b60e0b22</gtr:id><gtr:otherNames>Benson RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>56dd7b6ed377d8.06739389</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9AD94E2-C77D-4DB0-A000-AA28710D5554</gtr:id><gtr:title>Antigen depot is not required for alum adjuvanticity.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15360c76900df1668536b1e54257a86d"><gtr:id>15360c76900df1668536b1e54257a86d</gtr:id><gtr:otherNames>Hutchison S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>pm_5435aae5aae6059ad</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>273675F7-857B-4382-A972-3B552A181E13</gtr:id><gtr:title>Tracking dendritic cells in vivo.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a632c6a61c42bb312c1a72471a6a3f01"><gtr:id>a632c6a61c42bb312c1a72471a6a3f01</gtr:id><gtr:otherNames>Rush CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>pm_53cc033c033d17cb4</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/E00069X/2</gtr:identifier></gtr:identifiers><gtr:projectHierarchy><gtr:parents><gtr:parent><gtr:id>882B3519-40A6-4111-9EDF-3CE03532F4A3</gtr:id><gtr:grantRef>BB/E00069X/1</gtr:grantRef><gtr:amount>370236.54</gtr:amount><gtr:start>2007-05-01</gtr:start><gtr:end>2009-07-31</gtr:end><gtr:children><gtr:child rel="Transfer"><gtr:id>76342031-F399-444D-9050-E51BF781B97B</gtr:id><gtr:grantRef>BB/E00069X/2</gtr:grantRef><gtr:amount>101213.33</gtr:amount><gtr:start>2009-08-01</gtr:start><gtr:end>2010-07-31</gtr:end><gtr:children/></gtr:child></gtr:children></gtr:parent></gtr:parents></gtr:projectHierarchy><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>